These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19568)

  • 21. Opsonization of pneumococci by whole serum from sickle cell disease patients.
    Bloch EF; Castro O; Gregory JE; Okoh C
    J Natl Med Assoc; 1984 Feb; 76(2):179-82. PubMed ID: 6708126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions.
    Robertson J; Caldwell JR; Castle JR; Waldman RH
    J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consumptive opsoninopathy: possible pathogenesis in lethal and opportunistic infections.
    Alexander JW; McClellan MA; Ogle CK; Ogle JD
    Ann Surg; 1976 Dec; 184(6):672-8. PubMed ID: 793541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heat labile opsonin system to pneumococcus.
    Shin HS; Smith MR; Winkelstein J; Nicholson A
    Birth Defects Orig Artic Ser; 1975; 11(1):563-6. PubMed ID: 238689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Host defense against opportunist microorganisms following trauma. II. Changes in complement and immunoglobulins in patients with abdominal trauma and in septic patients without trauma.
    Bjornson AB; Altemeier WA; Bjornson HS
    Ann Surg; 1978 Jul; 188(1):102-8. PubMed ID: 666370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of immunoglobulin in the interaction of pneumococci and the properdin pathway: evidence for its specificity and lack of requirement for the Fc portion of the molecule.
    Winkelstein JA; Shin HS
    J Immunol; 1974 May; 112(5):1635-42. PubMed ID: 4150446
    [No Abstract]   [Full Text] [Related]  

  • 27. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway.
    Yuste J; Sen A; Truedsson L; Jönsson G; Tay LS; Hyams C; Baxendale HE; Goldblatt F; Botto M; Brown JS
    Infect Immun; 2008 Aug; 76(8):3761-70. PubMed ID: 18541650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunofluorescence patterns in chronic membranoproliferative glomerulonephritis (MPGN).
    Belgiojoso GB; Tarantino A; Bazzi C; Colasanti G; Guerra L; Durante A
    Clin Nephrol; 1976 Jul; 6(1):303-10. PubMed ID: 782750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capillary transport of immunoglobulins and complement proteins to the interstitial fluid and lymph.
    Olszewski WL; Engeset A
    Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):57-65. PubMed ID: 749810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breakdown products of C3 and factor B in hemolytic-uremic syndrome.
    Kim Y; Miller K; Michael AF
    J Lab Clin Med; 1977 Apr; 89(4):845-50. PubMed ID: 845484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for quantitative variability of bacterial opsonic requirements.
    Guckian JC; Christensen WD; Fine DP
    Infect Immun; 1978 Mar; 19(3):822-6. PubMed ID: 25243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency.
    Bjornson AB; Lobel JS
    J Clin Invest; 1987 Feb; 79(2):388-98. PubMed ID: 3805275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opsonins: their function, identity, and clinical significance.
    Winkelstein JA
    J Pediatr; 1973 May; 82(5):747-53. PubMed ID: 4144636
    [No Abstract]   [Full Text] [Related]  

  • 34. Alternative complement pathway activity in sera from patients with sickle cell disease.
    Koethe SM; Casper JT; Rodey GE
    Clin Exp Immunol; 1976 Jan; 23(1):56-60. PubMed ID: 816581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.
    Vu VP; Gifford GB; Chen F; Benasutti H; Wang G; Groman EV; Scheinman R; Saba L; Moghimi SM; Simberg D
    Nat Nanotechnol; 2019 Mar; 14(3):260-268. PubMed ID: 30643271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement and immunoglobulin levels in early childhood in homozygous sickle cell disease.
    De Ceulaer K; Forbes M; Maude GH; Pagliucca A; Serjeant GR
    J Clin Lab Immunol; 1986 Sep; 21(1):37-41. PubMed ID: 3806650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
    Day NK; Schreiber RD; Götze O; Müller-Eberhard HJ
    Scand J Immunol; 1976; 5(6-7):715-20. PubMed ID: 981969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of immunoglobulins M and G, complement, and properdin to the intracellular killing of Escherichia coli by polymorphonuclear leukocytes.
    Menzel J; Jungfer H; Gemsa D
    Infect Immun; 1978 Feb; 19(2):659-66. PubMed ID: 344218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biochemistry of opsonization: central role of the reactive thiolester of the third component of complement.
    Hostetter MK; Krueger RA; Schmeling DJ
    J Infect Dis; 1984 Nov; 150(5):653-61. PubMed ID: 6491376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.